CR11295A - 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos - Google Patents

2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Info

Publication number
CR11295A
CR11295A CR11295A CR11295A CR11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A
Authority
CR
Costa Rica
Prior art keywords
anilinopurin
onas
ttk
treatment
proliferative disorders
Prior art date
Application number
CR11295A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Ianin Simpson
Richard Andrew Ward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11295A publication Critical patent/CR11295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos quimicos de la formula (I) o una sal farmaceutica aceptable de estos, que poseen actividad inhibitoria frente a la cinasa del punto de control del huso.
CR11295A 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos CR11295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
CR11295A true CR11295A (es) 2010-05-28

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11295A CR11295A (es) 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Country Status (19)

Country Link
US (1) US20110118238A1 (es)
EP (1) EP2212326A1 (es)
JP (1) JP2010536841A (es)
KR (1) KR20100057650A (es)
CN (1) CN103298814A (es)
AU (1) AU2008290330A1 (es)
BR (1) BRPI0815709A2 (es)
CA (1) CA2696200A1 (es)
CO (1) CO6260060A2 (es)
CR (1) CR11295A (es)
DO (1) DOP2010000064A (es)
EA (1) EA201000341A1 (es)
EC (1) ECSP10010034A (es)
MX (1) MX2010002115A (es)
NI (1) NI201000032A (es)
NZ (1) NZ584138A (es)
SV (1) SV2010003491A (es)
WO (1) WO2009024824A1 (es)
ZA (1) ZA201001193B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651948A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
CN103443100B (zh) * 2010-12-17 2016-03-23 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪
EP2651945A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103370322B (zh) * 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
RS54044B1 (en) 2011-04-21 2015-10-30 Bayer Intellectual Property Gmbh TRIAZOLOPIRIDINI
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EA027544B1 (ru) 2012-07-10 2017-08-31 Байер Фарма Акциенгезельшафт Способ получения замещенных триазолопиридинов
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
PL3008062T3 (pl) 2013-06-11 2017-08-31 Bayer Pharma Aktiengesellschaft Pochodne proleki podstawionych triazolopirydyn
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
SI3558997T1 (sl) 2016-12-20 2021-07-30 Astrazeneca Ab Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
MX2022013054A (es) * 2020-04-17 2022-11-09 Chengdu Baiyu Pharmaceutical Co Ltd Derivados de imidazolidinona y uso medico de los mismos.
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
CN116685323A (zh) * 2020-12-21 2023-09-01 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
WO2023025160A1 (zh) * 2021-08-23 2023-03-02 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
EP4406955A1 (en) * 2021-09-23 2024-07-31 Chengdu Baiyu Pharmaceutical Co., Ltd. Crystal form of imidazolinone derivative
TW202402282A (zh) * 2022-07-13 2024-01-16 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用
WO2024017220A1 (zh) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用
WO2024125304A1 (zh) * 2022-12-13 2024-06-20 成都百裕制药股份有限公司 一种咪唑啉酮类化合物药物制剂及其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TWI398252B (zh) * 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
SV2010003491A (es) 2010-07-06
BRPI0815709A2 (pt) 2017-06-13
EP2212326A1 (en) 2010-08-04
WO2009024824A1 (en) 2009-02-26
US20110118238A1 (en) 2011-05-19
MX2010002115A (es) 2010-06-01
CN103298814A (zh) 2013-09-11
JP2010536841A (ja) 2010-12-02
ECSP10010034A (es) 2010-04-30
CA2696200A1 (en) 2009-02-26
NZ584138A (en) 2011-10-28
AU2008290330A1 (en) 2009-02-26
CO6260060A2 (es) 2011-03-22
EA201000341A1 (ru) 2010-10-29
DOP2010000064A (es) 2010-03-31
ZA201001193B (en) 2010-10-27
KR20100057650A (ko) 2010-05-31
NI201000032A (es) 2010-12-07

Similar Documents

Publication Publication Date Title
CR11295A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CL2018003511A1 (es) Derivados de pirazolopirimidina como inhibidor de quinasa.
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
EA201170872A1 (ru) Ингибиторы протеинкиназы
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112016024533A2 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
BR112016024484A2 (pt) derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
BR112016023967A2 (pt) derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
CU20100038A7 (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)